scholarly journals The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy

2020 ◽  
Vol 7 (4) ◽  
pp. e720 ◽  
Author(s):  
Francesca Castellani ◽  
Andrea Visentin ◽  
Marta Campagnolo ◽  
Alessandro Salvalaggio ◽  
Mario Cacciavillani ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Rating Scale ◽  
Kinase Inhibitor ◽  
Disability Score ◽  
Clinical Scales ◽  
Sum Score ◽  
Inflammatory Neuropathy ◽  
Bruton Tyrosine Kinase

ObjectiveTo assess whether neuropathy with anti-myelin-associated glycoprotein (MAG) antibody may improve after treatment with ibrutinib, an oral inhibitor of Bruton tyrosine kinase, we prospectively treated with ibrutinib a cohort of 3 patients with anti-MAG neuropathy and Waldenström macroglobulinemia (WM).MethodsAll 3 patients underwent bone marrow biopsy showing WM, with MYD88L265P mutated and CXCR4S338X wild type, and were started on ibrutinib 420 mg/die. Patients were assessed at baseline, at 3-6-9 months, and at 12 months in 2 patients with a longer follow-up, using Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score, INCAT sensory sum score, and Medical Research Council sum score. The modified International Cooperative Ataxia Rating Scale was performed in 2 patients, whereas it was not used in the patient with Parkinson disease as a major comorbidity. Responders were considered the patients improving by at least one point in 2 clinical scales.ResultsAll the patients reported an early and subjective benefit, consistent with the objective improvement, especially of the sensory symptoms as shown by clinical scales. Treatment was well tolerated.ConclusionThese preliminary data point to a possible efficacy of ibrutinib in anti-MAG antibody neuropathy, which is the most common disabling paraproteinemic neuropathy, where active treatment is eagerly needed.Classification of evidenceThis study provides Class IV evidence that for patients with anti-MAG antibody neuropathy, ibrutinib improves neuropathy symptoms.

scholarly journals The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells

2011 ◽  
Vol 13 (4) ◽  
pp. R115 ◽  
Author(s):  
Betty Y Chang ◽  
Min Huang ◽  
Michelle Francesco ◽  
Jun Chen ◽  
Jeremy Sokolove ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Autoimmune Arthritis ◽  
Effector Cells ◽  
Bruton Tyrosine Kinase

scholarly journals Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells

2016 ◽  
Vol 23 (14) ◽  
pp. 3734-3743 ◽  
Author(s):  
Viralkumar Patel ◽  
Kumudha Balakrishnan ◽  
Elena Bibikova ◽  
Mary Ayres ◽  
Michael J. Keating ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Lymphocytic Leukemia ◽  
Leukemia Cells ◽  
Bruton Tyrosine Kinase

Surgery of locally advanced and metastatic kidney cancer after tyrosine kinase inhibitors therapy: single institute experience

2018 ◽  
Vol 104 (5) ◽  
pp. 388-393
Author(s):  
Alberto De Gobbi ◽  
Davide Biasoni ◽  
Mario Catanzaro ◽  
Nicola Nicolai ◽  
Luigi Piva ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Kinase Inhibitors ◽  
Kinase Inhibitor ◽  
Target Therapy ◽  
Tnm Classification ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Metastatic Tumor ◽  
Grade Ii

Purpose: Renal cell carcinoma (RCC) is the most common tumor of the kidney. Considering the TNM classification of 2009, locally advanced and metastatic diseases are included in the groups stage III and IV. The surgical treatment of these tumors could be divided into 3 categories: (1) curative (nephrectomy and/or metastasectomy), (2) cytoreductive, and (3) palliative. Targeted agents showed impressive antitumor efficacy and prolongation of progression-free survival. The integration between target therapy and surgery in patients with locally advanced or metastatic RCC has sometimes facilitated surgery. We aimed to evaluate patients’ response to tyrosine kinase inhibitor (TKI) therapy and the feasibility of surgery after that and to observe complications related to surgery. Methods: From February 2007 to September 2014 in the Istituto Tumori of Milan, IRCCS, we selected patients with locally advanced or metastatic diseases, treated with target therapy before surgery (which comprised nephrectomy or partial nephrectomy, cytoreductive surgery, and metastasectomy) and cryoablation. Results: We selected 33 patients who underwent surgery after TKI therapy. As for response to TKIs, 20 patients (60%) had stable disease, 9 patients (28%) had a partial response, and 4 patients (12%) had progressive disease. A total of 17 patients (51%) presented complications directly or indirectly related to surgery and most of those were classified as grade II Clavien-Dindo score. Conclusions: The association between TKI and surgery seems to have no contraindications. Our dataset provides an example of how surgery after TKI is possible in locally advanced metastatic tumor and does not have an excessive rate of postoperative complications.

scholarly journals Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Blood ◽  
2017 ◽  
Vol 129 (20) ◽  
pp. 2808-2810 ◽  
Author(s):  
Harriet S. Walter ◽  
Sandrine Jayne ◽  
Simon A. Rule ◽  
Guillaume Cartron ◽  
Franck Morschhauser ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Long Term Follow Up

scholarly journals Ibrutinib Treatment of a Patient with Relapsing Chronic Lymphocytic Leukemia and Sustained Remission of Richter Syndrome

2017 ◽  
Vol 103 (1_suppl) ◽  
pp. S37-S40 ◽  
Author(s):  
Elisa Albi ◽  
Stefano Baldoni ◽  
Patrizia Aureli ◽  
Erica Dorillo ◽  
Beatrice Del Papa ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Kinase Inhibitor ◽  
Rare Event ◽  
Lymphocytic Leukemia ◽  
Sustained Remission ◽  
Richter Syndrome ◽  
Positron Emission ◽  
Bruton Tyrosine Kinase ◽  
Tomography Scan

Purpose Richter syndrome (RS) is a rare event in chronic lymphocytic leukemia (CLL) that is influenced by biological factors and prior CLL treatments. Ibrutinib is a Bruton tyrosine kinase inhibitor that has shown remarkable efficacy in CLL; however, little is known about its relationship to RS. We report a case of ibrutinib efficacy against CLL in a patient with prolonged remission of RS. Methods The patient was diagnosed with CLL in 2003. Biological findings at onset included absent ZAP70 expression, mutated IGVH, and NOTCH1 mutation. He was treated with FCR with partial response. In 2013, he progressed to RS, not clonally related to the underlying CLL. The patient was treated with anthracycline- and platinum-based regimens, obtaining a complete remission. After 3 years, he presented a CLL progression with worsening lymphocytosis, anemia, thrombocytopenia, increased splenomegaly, and lymphadenopathies. Positron emission tomography-computed tomography scan excluded pathologic uptake. Thus, he was started on ibrutinib. Results At 12 months’ follow-up, we observed white blood cell normalization, increased hemoglobin and platelet levels, disappearance of lymphadenopathy, and spleen size reduction. Therapy was well-tolerated with no evidence of RS. Conclusion This case demonstrates sustained RS remission in a patient with CLL under ibrutinib therapy, thus improving our knowledge on the use of this new drug in CLL and beyond.

Sign in / Sign up

Export Citation Format

Share Document